125-160kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1.Review Rom J Morphol Embryol . 2018;59(2):455-467.
Vascular endothelial cell growth factor (VEGF) and VEGF receptor 2 (VEGF-R2) are closely related to angiogenesis in glioma. A number of phosphorylated sites, such as Y801, Y951, Y1175, and Y1214 in the VEGF-R2 intracellular domains mediate critical signal transductions, including PI3K/AKT, MAPK, and PKC pathways. Main functions of VEGF-R2 include increasing the expression of VEGF and inducing tumor angiogenesis. In addition, VEGF plays a role in promoting vascular endothelial cell division and angiogenesis through VEGF-R2 and is also involved in promoting the aggressive growth of tumors. In the kidney, VEGF is almost exclusively expressed in glomerular and tubular epithelial cells, while the VEGF-R2 is mainly present in glomerular and tubular endothelial cells, as well as in interstitial cells. The present study shows that VEGF-R2 overexpression in advanced thyroid cancer maintains cancer malignancy and cell survival. Thus, selective targeting of VEGFR2/KDR signaling may be a potential strategy for advanced thyroid cancer treatment.
1μg (R: reducing condition, N: non-reducing condition).
Immobilized VEGF165 Protein, Human (Cat. No. UA040019) at 2.0μg/mL (100μL/well) can bind VEGF R2/Flk-1/KDR Fc Chimera Protein, Mouse (Cat. No. UA010876) with EC50 of 5.17-7.70 ng/mL.